Search

Your search keyword '"Can G."' showing total 1,143 results

Search Constraints

Start Over You searched for: Author "Can G." Remove constraint Author: "Can G."
1,143 results on '"Can G."'

Search Results

1. Effect of FADS1 SNPs rs174546, rs174547 and rs174550 on blood fatty acid profiles and plasma free oxylipins

2. Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

3. Harnessing Oxylipins and Inflammation Modulation for Prevention and Treatment of Colorectal Cancer

4. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

5. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma

6. Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma

7. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation

10. Quality control for next-generation liquefaction case histories

13. Harnessing Oxylipins and Inflammation Modulation for Prevention and Treatment of Colorectal Cancer.

15. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.

18. Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

19. Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

20. Supplementary Methods from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

21. Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

22. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

25. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

26. Striated muscle-specific β1D-integrin and FAK are involved in cardiac myocyte hypertrophic response pathway

27. Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

28. Data from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

29. Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

30. Supplementary Methods from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

31. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

33. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288 participants

35. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin

36. INCIDENCE OF ANTERIOR UVEITIS IN AXIAL SPONDYLOARTHRITIS DURING SECUKINUMAB TREATMENT: TWO YEARS REAL LIFE EXPERIENCE FROM TURKBIO REGISTRY

37. COVID-19 VACCINATION OF SPONDYLOARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: REAL-LIFE DATA

42. A NEW SCREENING TOOL FOR PSORIATIC ARTHRITIS IN PSORIASIS PATIENTS: TURPAS

45. Risk factors for malignancy in systemic sclerosis patients

48. AB1088 COVID-19 VACCINATION OF SPONDYLOARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: REAL-LIFE DATA

49. AB0420 UNINTENTIONAL MONOTHERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB AND DRUG SURVIVAL RATE OF TOFACITINIB

Catalog

Books, media, physical & digital resources